
David
982 posts

David
@BarnyardBull72
Trader 📈 bio-hacker 🧬 and weight lifter 💪🏼 Peptides are the future. Disclosure: Opinions only, not investment advice. DYOR. High risk, High reward stocks.



the weight loss efficacy between both $NVO and $LLY oral pills are a few % and likely negligible in the real world. i think the differentiator comes down to having more flexibility in dosing as a way to deal with side effects and Lilly’s drug clearly wins on this. more doses per mg, and you can cut the pill in half without affecting absorption to allow for more tailored dosing. oral sema is limited by its snac so you can’t break it in half, and the jump from 9mg to 25mg is, ehh, a big one. people are gonna feel a wham of side effects on the highest dose and likely churn or switch to the injectable. either way, lilly wins here imo

$LEXX add to the Bull case and most importantly 🚨 🐂 Lexaria is currently in an exclusive and extended MTA with a global Pharma company speculated to be $NVO or $LLY. Simultaneously they are having discussions with several other Pharma companies regarding the dehydraTECH platform. 🔥🔥🔥😮💨☝🏻🤝

$LEXX — Bullish 🚀 🏷️ $0.808 Lexaria to Begin New Human Clinical Study in GLP-1 Bull Case: + Lexaria is initiating a new human clinical study (Pilot Study #7) in the highly sought-after GLP-1 market, a sector currently experiencing immense investor interest and growth (e.g., Wegovy, Rybelsus). + The study introduces significant new DehydraTECH enhancements, including an oral tablet formulation designed to mimic properties of Novo Nordisk's successful Rybelsus/Wegovy tablets and the first multi-dose, multi-week evaluation of SNAC-formulated test articles in humans, aiming for superior PK performance. + The study is fully funded from existing corporate resources, mitigating immediate dilution concerns, and is explicitly aimed at generating interest from pharmaceutical partners, which would be a major catalyst for the company. Bear Case: − The study is in its very early stages, with ethics approval pending and patient recruitment yet to begin, meaning actual clinical results or data are many weeks to months away. − Clinical trials carry inherent risks, and there is no guarantee that the study will achieve its desired outcomes, match or exceed the performance of commercial products, or lead to successful partnerships. #pennystocks #daytrading Not financial advice. DYOR.








